Randomized controlled trials (RCTs) have investigated the use of colchicine and conventional therapy for reducing the recurrence of pericarditis in patients with acute pericarditis or post-pericardiotomy syndrome. However, the benefits of these treatments are variable.
Studies were retrieved from PubMed, the Cochrane Library, and the EMBASE database.
We identified nine RCTs with 1832 patients and a mean follow-up of 13.1 months. Overall, colchicine therapy significantly decreased the risk of pericarditis recurrence (odds ratio, OR 0.42; 95 % confidence interval, CI 0.33-0.52; P < 0.001; I-2 = 17.0 %). Colchicine therapy was associated with significantly lower rates of pericarditis-associated rehospitalization (OR 0.29; 95 % CI 0.16-0.53; P < 0.0001; I-2 = 0.0 %) and persistence of symptoms (OR 0.29; 95 % CI, 0.21-0.41; P = 0.000; I-2 = 0.0 %) at 72 h. Adverse events were higher in the colchicine group (relative risk, RR 1.48; 95 % CI, 1.06-2.07; P = 0.02; I-2 = 0.0 %). Subgroup analysis showed that recurrence of pericarditis was significantly lower in the colchicine therapy group, irrespective of prednisone use and the cause of pericarditis.
Colchicine significantly decreases the rate of pericarditis recurrence, regardless of prednisone use and the cause of pericarditis. Larger studies are needed to confirm this effect.
[1]Chinese PLA, Gen Staff Dept, Guard Bur, Hlth Div, Beijing, Peoples R China.
[2]Peoples Hosp Rizhao, Dept Cardiol, Rizhao, Shandong, Peoples R China.
[3]Second Peoples Hosp Yunnan Prov, Dept Cardiovasc Surg, Kunming, Yunnan, Peoples R China.
[4]Capital Med Univ, Beijing Chao Yang Hosp, Dept Pediat, Beijing, Peoples R China.
(8.0+极速模式)